NASDAQ:ATAI Atai Life Sciences (ATAI) Stock Price, News & Analysis → Grab Your Free Bitcoin Today! (From Crypto Swap Profits) (Ad) Free ATAI Stock Alerts $1.97 +0.18 (+10.06%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$1.80▼$2.0450-Day Range$1.63▼$2.1952-Week Range$1.03▼$2.39Volume2.95 million shsAverage Volume1.55 million shsMarket Capitalization$327.04 millionP/E RatioN/ADividend YieldN/APrice Target$17.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Atai Life Sciences alerts: Email Address Atai Life Sciences MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside788.3% Upside$17.50 Price TargetShort InterestHealthy4.52% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.39Based on 12 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.69) to ($0.73) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.09 out of 5 starsMedical Sector602nd out of 938 stocksPharmaceutical Preparations Industry269th out of 417 stocks 3.5 Analyst's Opinion Consensus RatingAtai Life Sciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $17.50, Atai Life Sciences has a forecasted upside of 788.3% from its current price of $1.97.Amount of Analyst CoverageAtai Life Sciences has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted4.52% of the float of Atai Life Sciences has been sold short.Short Interest Ratio / Days to CoverAtai Life Sciences has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Atai Life Sciences has recently increased by 47.59%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAtai Life Sciences does not currently pay a dividend.Dividend GrowthAtai Life Sciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ATAI. Previous Next 3.0 News and Social Media Coverage News SentimentAtai Life Sciences has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Atai Life Sciences this week, compared to 1 article on an average week.Search Interest25 people have searched for ATAI on MarketBeat in the last 30 days. This is an increase of 92% compared to the previous 30 days.MarketBeat Follows13 people have added Atai Life Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 117% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Atai Life Sciences insiders have not sold or bought any company stock.Percentage Held by Insiders30.00% of the stock of Atai Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 28.41% of the stock of Atai Life Sciences is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Atai Life Sciences are expected to decrease in the coming year, from ($0.69) to ($0.73) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Atai Life Sciences is -4.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Atai Life Sciences is -4.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAtai Life Sciences has a P/B Ratio of 1.23. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap ProfitsClaim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.Secure Your Spot Now About Atai Life Sciences Stock (NASDAQ:ATAI)ATAI Life Sciences N.V., a clinical-stage biopharmaceutical company, engages in acquiring, incubating, and developing various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its principal clinical programs include RL-007, a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; GRX-917, a deuterated etifoxine for anxiety disorders; VLS-01 a N,N-Dimethyltryptamine for treatment resistant depression (TRD); DMX-1002, an oral formulation of ibogaine, a cholinergic, glutamatergic and monoaminergic receptor modulator that is a naturally occurring psychedelic product isolated from a West African shrub for the treatment of opioid use disorders (OUD); and EMP-01, an oral formulation of an MDMA derivative being developed for the treatment of post-traumatic stress disorder. The company's other clinical programs comprise PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; and KUR-101, a formulation of deuterated mitragynine for the treatment of OUD. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.Read More ATAI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ATAI Stock News HeadlinesMarch 28, 2024 | msn.comIntranasal 5-MeO-DMT Clinical Trial Offers Hope For Treatment-Resistant DepressionMarch 28, 2024 | benzinga.comRecap: ATAI Life Sciences Q4 EarningsMarch 29, 2024 | WealthPress (Ad)$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…March 28, 2024 | proactiveinvestors.comatai Life Sciences funded into 2026; sets sights on key milestones for its psychedelic therapiesMarch 28, 2024 | msn.comATAI Life Sciences GAAP EPS of -$0.12 beats by $0.04March 28, 2024 | globenewswire.comatai Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate and Clinical HighlightsMarch 27, 2024 | proactiveinvestors.comatai-backed Beckley Psytech unveils positive results from DMT for treatment-resistant depression studyMarch 27, 2024 | markets.businessinsider.comAtai Life: Beckley Psytech's Phase 2a Trial Of BPL-003 Positive In Treatment Resistant DepressionMarch 29, 2024 | WealthPress (Ad)$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…March 27, 2024 | finance.yahoo.comatai Life Sciences Announces Positive Initial Results from Beckley Psytech’s Phase 2a Open Label Study of BPL-003 (Intranasal 5-MeO-DMT) in Treatment Resistant DepressionMarch 27, 2024 | globenewswire.comatai Life Sciences Announces Positive Initial Results from Beckley Psytech's Phase 2a Open Label Study of BPL-003 (Intranasal 5-MeO-DMT) in Treatment Resistant DepressionMarch 15, 2024 | morningstar.comThinking about buying stock in Lexicon Pharmaceuticals, Cassava Sciences, Clearside Biomedical, Lantern Pharma, or ATAI Life Sciences?March 14, 2024 | finance.yahoo.comCaris Life Sciences to Showcase Research at 2024 SGO Annual Meeting on Women's CancerMarch 14, 2024 | msn.comPsychedelic drug ibogaine hailed as healing. U.S. patients ask why it’s illegal.March 12, 2024 | finance.yahoo.comatai Life Sciences advances VLS-01 for treatment-resistant depressionMarch 8, 2024 | finance.yahoo.comATAI Apr 2024 1.500 putMarch 8, 2024 | finance.yahoo.comATAI Apr 2024 2.000 callMarch 4, 2024 | proactiveinvestors.comatai Life Sciences doses first patient in Phase 1b study of its optimized oral DMT formulationMarch 4, 2024 | globenewswire.comatai Life Sciences Announces First Participant Dosed in Phase 1b Trial of VLS-01February 28, 2024 | globenewswire.comatai Life Sciences to Participate in the Upcoming TD Cowen 44th Annual Health Care ConferenceFebruary 22, 2024 | benzinga.comATAI Life Sciences Stock (NASDAQ:ATAI), Quotes and News SummaryFebruary 17, 2024 | finance.yahoo.comATAI Mar 2024 2.000 callFebruary 15, 2024 | finance.yahoo.comATAI Feb 2024 1.500 putFebruary 15, 2024 | finance.yahoo.comATAI Mar 2024 1.500 putFebruary 15, 2024 | finance.yahoo.comATAI Aug 2024 1.500 callFebruary 14, 2024 | theglobeandmail.comBreaking: The US FDA Just Granted Priority Review of an MDMA Treatment for PTSDFebruary 7, 2024 | msn.comATAI Life Sciences Announces New CFO Appointment and TransitionSee More Headlines Receive ATAI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Atai Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/10/2023Today3/28/2024Next Earnings (Estimated)3/29/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ATAI CUSIPN/A CIK1420529 Webwww.atai.net.cn Phone49-89-2153-9035FaxN/AEmployees133Year FoundedN/APrice Target and Rating Average Stock Price Target$17.50 High Stock Price Target$20.00 Low Stock Price Target$15.00 Potential Upside/Downside+788.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.45) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-152,380,000.00 Net Margins-20,043.11% Pretax Margin-18,050.30% Return on Equity-54.90% Return on Assets-47.37% Debt Debt-to-Equity Ratio0.06 Current Ratio10.96 Quick Ratio10.96 Sales & Book Value Annual Sales$230,000.00 Price / Sales1,421.91 Cash FlowN/A Price / Cash FlowN/A Book Value$1.60 per share Price / Book1.23Miscellaneous Outstanding Shares166,010,000Free Float116,207,000Market Cap$327.04 million OptionableOptionable Beta0.97 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Christian Angermayer (Age 46)Founder & Chairman of the Supervisory Board Comp: $70kMr. Florian Brand (Age 37)Co-founder & CEO Comp: $835.44kDr. Srinivas G. Rao M.D. (Age 55)Ph.D., Co-Founder & Chief Scientific Officer Comp: $834.15kMr. Stephen B. Bardin (Age 33)Advisor Comp: $651.32kMs. Anne JohnsonChief Financial OfficerDr. Michael Raven Ph.D.Senior Vice President of OperationsMr. Frank Stegert (Age 43)Vice President of Investment & Venture Management Mr. Ryan BarrettSenior VP, General Counsel & Corporate SecretaryDr. Glenn Short Ph.D.Senior Vice President of Early DevelopmentDr. Sahil V. Kirpekar M.D. (Age 39)Chief Business Officer More ExecutivesKey CompetitorsXeris BiopharmaNASDAQ:XERSNanobiotixNASDAQ:NBTXRAPT TherapeuticsNASDAQ:RAPTVerastemNASDAQ:VSTMAC ImmuneNASDAQ:ACIUView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Sold 113,729 shares on 3/11/2024Ownership: 0.247%Goldman Sachs Group Inc.Bought 55,002 shares on 3/1/2024Ownership: 0.067%Virtu Financial LLCBought 29,140 shares on 2/26/2024Ownership: 0.018%Prelude Capital Management LLCBought 17,952 shares on 2/15/2024Ownership: 0.011%Citadel Advisors LLCSold 4,800 shares on 2/15/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions ATAI Stock Analysis - Frequently Asked Questions Should I buy or sell Atai Life Sciences stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Atai Life Sciences in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ATAI shares. View ATAI analyst ratings or view top-rated stocks. What is Atai Life Sciences' stock price target for 2024? 2 Wall Street analysts have issued 1 year price objectives for Atai Life Sciences' shares. Their ATAI share price targets range from $15.00 to $20.00. On average, they expect the company's stock price to reach $17.50 in the next year. This suggests a possible upside of 788.3% from the stock's current price. View analysts price targets for ATAI or view top-rated stocks among Wall Street analysts. How have ATAI shares performed in 2024? Atai Life Sciences' stock was trading at $1.41 on January 1st, 2024. Since then, ATAI stock has increased by 39.7% and is now trading at $1.97. View the best growth stocks for 2024 here. Are investors shorting Atai Life Sciences? Atai Life Sciences saw a increase in short interest in March. As of March 15th, there was short interest totaling 5,210,000 shares, an increase of 47.6% from the February 29th total of 3,530,000 shares. Based on an average daily trading volume, of 1,480,000 shares, the short-interest ratio is currently 3.5 days. Approximately 4.5% of the company's shares are sold short. View Atai Life Sciences' Short Interest. When is Atai Life Sciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, March 29th 2024. View our ATAI earnings forecast. How were Atai Life Sciences' earnings last quarter? Atai Life Sciences (NASDAQ:ATAI) announced its quarterly earnings results on Thursday, August, 10th. The company reported ($0.21) EPS for the quarter, meeting analysts' consensus estimates of ($0.21). The business earned $0.17 million during the quarter. Atai Life Sciences had a negative trailing twelve-month return on equity of 54.90% and a negative net margin of 20,043.11%. What ETFs hold Atai Life Sciences' stock? ETFs with the largest weight of Atai Life Sciences (NASDAQ:ATAI) stock in their portfolio include AdvisorShares Psychedelics ETF (PSIL), Virtus LifeSci Biotech Clinical Trials ETF (BBC) and Direxion Moonshot Innovators ETF (MOON).Simplify Propel Opportunities ETF (SURI). What other stocks do shareholders of Atai Life Sciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Atai Life Sciences investors own include Alphabet (GOOG), Baidu (BIDU), Costco Wholesale (COST), MannKind (MNKD), NVIDIA (NVDA), Schlumberger (SLB), Twitter (TWTR), Adobe (ADBE), Allergan (AGN) and Achaogen (AKAO). When did Atai Life Sciences IPO? Atai Life Sciences (ATAI) raised $200 million in an IPO on Friday, June 18th 2021. The company issued 14,300,000 shares at a price of $13.00-$15.00 per share. Credit Suisse, Citigroup, Cowen and Berenberg acted as the underwriters for the IPO and Cantor, RBC Capital Markets and Canaccord Genuity were co-managers. Who are Atai Life Sciences' major shareholders? Atai Life Sciences' stock is owned by a number of retail and institutional investors. Top institutional investors include Mirae Asset Global Investments Co. Ltd. (0.38%), Vanguard Group Inc. (0.25%), Vanguard Group Inc. (0.25%), Barclays PLC (0.15%), AdvisorShares Investments LLC (0.12%) and Goldman Sachs Group Inc. (0.07%). Insiders that own company stock include Apeiron Investment Group Ltd, Christian Angermayer, Florian Brand, Gregory L Weaver and Srinivas Rao. View institutional ownership trends. How do I buy shares of Atai Life Sciences? Shares of ATAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ATAI) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI healthcare stock poised for 36,996% growth?Behind the MarketsBill Gates is all about this tiny $2 stockTimothy Sykes Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atai Life Sciences Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.